Abstract
Long-term proteasome inhibition (LTPI) improves outcomes in NDMM vs non-proteasome inhibitor (PI)-based therapy. However, efficacy improvements seen in clinical trials are often not achieved in real-world (RW) settings, and duration of PI-based therapy is typically shorter in US non transplant NDMM RW patients (pts) vs in phase 3 trials. This may be due to poor treatment adherence, burden of parenteral administration, comorbidities, financial burden, distance from treatment center, physician/pt preference, or toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
